MA
TTNP

MCF Advisors’s Titan Pharmaceuticals TTNP Stock Holding History

MCF Advisors’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-165
Closed -$538 – 1019
2024
Q4 		$538 Hold
165
– – ﹤0.01% 949
2024
Q3 		$870 Hold
165
– – ﹤0.01% 919
2024
Q2 		$920 Hold
165
– – ﹤0.01% 920
2024
Q1 		$1.18K Buy
+165
New +$1.16K ﹤0.01% 868

Other funds holding TTNP

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GWSA
Global Wealth Strategies & Associates Denver, Colorado $528M AUM 23.18% 1-Year Est. Return
CSC
Caldwell Sutter Capital Sausalito, California $246M AUM 23.62% 1-Year Est. Return

MCF Advisors's TTNP Position: Q1 2025 in Review

MCF Advisors sold out of Titan Pharmaceuticals (TTNP) in Q1 2025, closing a stake of 165 shares — an estimated $538 sold.

MCF Advisors first reported a position in TTNP in Q1 2024 and held it in 4 quarters. The position peaked at $1.18K in Q1 2024. 17 funds tracked by Wall St. Rank hold TTNP as of Q1 2025.

  • MCF Advisors reported no remaining Titan Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • MCF Advisors sold 165 Titan Pharmaceuticals shares in Q1 2025, an estimated $538.
  • MCF Advisors first reported a position in Titan Pharmaceuticals in Q1 2024 and held it in 4 quarters.
  • MCF Advisors's Titan Pharmaceuticals position peaked at $1.18K in Q1 2024.
  • 17 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q1 2025.

Based on MCF Advisors's 13F filing for Q1 2025, filed 6 May 2025.